

Hologic, Inc.(HOLX)

\$75.05 (As of 11/06/20)

Price Target (6-12 Months): **\$86.00**

Long Term: 6-12 Months

Zacks Recommendation:

Outperform

(Since: 11/06/20)

Prior Recommendation: Neutral

Short Term: 1-3 Months

Zacks Rank: (1-5)

1-Strong Buy

Zacks Style Scores:

VGM:B

Value: C

Growth: B

Momentum: A

Summary

Hologic exited fiscal fourth quarter with better-than-expected results. Robust bottom and top-line growth amid the pandemic is encouraging. Organic revenue growth and growth in Diagnostic revenues, led by the Molecular Diagnostics arm, buoy optimism. Robust demand for Hologic's COVID-19-related products and ongoing recovery in other segments have enabled the company to provide fiscal first-quarter guidance, which instills confidence in investors. Expansion of both margins looks encouraging. Regulatory approvals for the company's diagnostic tests are encouraging. For the past six months, Hologic has been outperforming its industry. Yet, fall in its other segments' revenues due to the pandemic is worrying. Stiff competition and foreign exchange fluctuations are other headwinds. A weak solvency and capital structure is also deterring.


Price, Consensus & Surprise



Data Overview

52-Week High-Low	\$77.49 - \$26.49
20-Day Average Volume (Shares)	1,851,296
Market Cap	\$19.4 B
Year-To-Date Price Change	43.8%
Beta	1.39
Dividend / Dividend Yield	\$0.00 / 0.0%
Industry	Medical - Instruments
Zacks Industry Rank	Bottom 34% (165 out of 249)

Sales and EPS Growth Rates (Y/Y %)



Last EPS Surprise	69.7%
Last Sales Surprise	7.7%
EPS F1 Estimate 4-Week Change	2.3%
Expected Report Date	NA
Earnings ESP	13.5%
P/E TTM	18.8
P/E F1	12.1
PEG F1	0.8
P/S TTM	5.2

Sales Estimates (millions of \$)

	Q1	Q2	Q3	Q4	Annual*
2022					3,747 E
2021	1,061 E	1,089 E	980 E	926 E	4,236 E
2020	851 A	756 A	823 A	1,347 A	3,776 A

EPS Estimates

	Q1	Q2	Q3	Q4	Annual*
2022	\$1.26 E	\$1.05 E	\$0.99 E	\$0.93 E	\$4.23 E
2021	\$1.86 E	\$1.69 E	\$1.36 E	\$1.28 E	\$6.20 E
2020	\$0.61 A	\$0.57 A	\$0.75 A	\$2.07 A	\$3.98 A

*Quarterly figures may not add up to annual.

The data in the charts and tables, including the Zacks Consensus EPS and Sales estimates, is as of 11/06/2020. The reports text is as of 11/09/2020.

Overview

Headquartered in Bedford, MA, Hologic Inc. develops, manufactures, and supplies diagnostics, medical imaging systems and surgical products which cater to the healthcare needs of women.

Hologic operates through the following four segments:


Diagnostics (35.8% of total revenues in 4Q19): With the Gen-Probe acquisition, Hologic currently offers APTIMA family of assays that includes the APTIMA Combo 2 assay, which feature the APTIMA CT and APTIMA GC assays, the APTIMA HPV assay and the APTIMA Trichomonas assay. Other products include the ThinPrep system, primarily used in cytology applications. In the fourth quarter of fiscal 2019, this segment registered 6.2% growth year-over-year.

Breast Health (38.2% of total revenues in 4Q19): Products include a broad portfolio of breast imaging and related products and accessories, including digital and film-based mammography systems, computer-aided detection (CAD), breast biopsy guidance systems, minimally invasive breast biopsy and tissue extraction devices and breast brachytherapy products. In the fourth quarter of fiscal 2019, this segment registered 6.3% growth year-over-year.

GYN Surgical (13.2% of total revenues in 4Q19): Products include the NovaSure endometrial ablation system – used in the treatment of heavy menstrual bleeding and the MyoSure hysteroscopic tissue removal system – which allows incision less removal of fibroids and polyps within the uterus. In the fourth quarter of fiscal 2019, this segment registered 6.6% growth year over year.

Medical Aesthetics (9.9% of total revenues in 4Q19): Hologic completed the divestiture of its Cynosure Medical Aesthetics business on Dec 30, 2019.

Skeletal Health (2.9% of total revenues in 3Q19): This segment includes dual-energy X-ray bone densitometry systems, an ultrasound-based osteoporosis assessment product, and Fluoroscans mini C-arm imaging products. In the fourth quarter of fiscal 2019, this segment registered 2.6% growth year over year.



Source: Zacks Investment Research

Reasons To Buy:

▲ **Share Price Movement:** For the past six months, Hologic has been outperforming its industry. The stock has gained 42.1% compared with the 20.1% rise of its industry. Hologic exited fiscal fourth quarter with better-than-expected results. Robust bottom- and top-line growth amid the pandemic-led business disruptions is encouraging. Rise in organic revenues is impressive as well. Growth in Diagnostic revenues, led by a stupendous improvement in the company's Molecular Diagnostics revenues, buoys optimism. Robust demand for the company's COVID-19-related products and ongoing recovery in other segments have enabled the company to provide fiscal first-quarter guidance, which instills confidence in investors. Expansion of both margins looks encouraging. Regulatory approvals for the company's diagnostic tests are encouraging.

Hologic's progress in the domestic and international markets, strong pipeline of products and solid performance delivered by the GYN Surgical and Molecular Diagnostics segments bolster our confidence.

▲ **Molecular Diagnostics Sees Growth on Coronavirus Tests:** Hologic's management is impressed with continued growth in the core molecular diagnostics sub-segment, which accounted for 87.2% of total Diagnostics revenues in the fiscal fourth quarter. Molecular Diagnostics sales increased 370.8% at constant exchange rate or CER. Global revenues for molecular diagnostics increased 626.4%.

Hologic, in October, announced the amendment of the FDA's Emergency Use Authorization (EUA) that was initially received for its Aptima SARS-CoV-2 assay (that runs on the company's fully automated Panther system) in May. Post the receipt of the amended EUA, the Aptima assay is now authorized for testing of asymptomatic individuals (without symptoms) along with those having symptoms of the COVID-19 infection.

In September, the company received the FDA's EUA for its Panther Fusion SARS-CoV-2 assay. The assay will be used to test asymptomatic individuals and those having symptoms of the COVID-19 infection.

Additionally, the FDA has authorized Hologic's pooling protocol, which was announced on Aug 11, for symptomatic testing with the Aptima SARS-CoV-2 assay.

The company generated solid revenues from strong customer adoption of Hologic's two SARS-CoV-2 assays that run on the Panther and Panther Fusion systems. Following the robust demand for the assays, Hologic is on track to scale up its molecular diagnostics manufacturing capacity.

▲ **GYN Surgical Holds Potential:** Over the past two years, the GYN Surgical business has transformed to the most profitable division of Hologic on a percentage basis banking on new leadership, strong strategic execution of new commercial models and new product launches.

Despite the fiscal fourth-quarter debacle of this segment where it fell 12.9% at CER, Hologic is optimistic about the faster-than-expected recovery of the segment. Although the company witnessed lower demand for semi-elective procedures during the quarter due to the ongoing pandemic, demand trends are gradually improving. Notably, the segment's performance exceeded Hologic's internal projections.

▲ **Growth Initiatives:** In order to streamline its operations and reduce cost of revenue, Hologic has been adopting a few significant strategies over the past few years. The company has invested deliberately and opportunistically in commercial areas where management has recognized a good return. These include Hologic's Genius marketing campaign in Breast Health, cervical cancer co-testing initiatives in Diagnostics, along with efforts to gain competitive market share with NovaSure. Per management, these strategic initiatives are already paying off through increased brand awareness, market share gains, and price stability, all of which will contribute to the company's higher sales.

Moreover, to strengthen its product pipeline, Hologic is working on innovations and product launches. In this regard we note that, the company has launched a cadence of products which are 3DQuorum Imaging Technology, powered by Genius AI in the United States and LOCalizer radiofrequency identification (RFID) tag for long-term placement in Europe. U.S. regulatory clearances, which include the Unifi Workspace reading solution and 3DQuorum AI imaging technology in Breast Health, and the Definity cervical dilator in GYN Surgical, are encouraging.

▲ **Focus on International Operations:** According to Hologic, global expansion will be a critical element of its growth strategy over the long term. While many of the company's best-in-class products command a leading share in the domestic market, they hold a disproportionately low market share internationally, indicating huge untapped potential.

The company's international sales have been a major catalyst over the past three years, with the major driver being the molecular diagnostics business. During the fourth quarter of fiscal 2020, international revenues for the Diagnostics segment rose 260.3% at CER, with Molecular Diagnostics being the primary driver. Hologic is increasingly focusing on commercial infrastructure. In Europe, the installed base of Panthers significantly improved by the end of the fiscal third quarter. By leveraging on this installed base, the company has signed contracts in various countries, thus securing about \$500 million of COVID testing revenues over the next four quarters. Notably, Hologic's largest contract is with the U.K. Department of Health.

Global growth in Molecular Diagnostics was primarily driven by increasing market share and utilization of the fully automated Panther system.

The overall promising international performance reflects the tremendous progress Hologic has made in building a sustainable growth engine through both organic and inorganic means, including the acquisitions of two European distributors.

Risks

- **Foreign Exchange Headwinds:** We remain worried about the significant challenges Hologic faced owing to unfavorable foreign currency impact that has been adversely affecting the company's overall performance in the past few quarters.
- **Dull Segmental Performance:** Hologic's performance across majority of its segments was disappointing, resulting from pandemic-led business disruptions. Revenues at the Breast Health segment declined 16.2% at CER primarily due to adverse impacts on demand for this segment's products, especially in the United States. This was the result of customers' focus on responding to the pandemic, delayed or reduced purchases of capital equipment and rescheduled routine screening appointments. Further, semi-elective procedure deferrals hurt GYN Surgical business, which fell 12.9% at CER.

- **Competitive Landscape:** Hologic operates in a highly competitive industry. Its mammography, related products and subsystems compete on a worldwide basis with products offered by a number of competitors, including General Electric Company (GE), Siemens, Koninklijke Philips NV, or Philips, Planmed Oy, or Planmed, Agfa-Gevaert N.V., or Agfa, Carestream Health, Inc., FUJIFILM Holdings Corporation, or Fuji, I.M.S., and Toshiba Corporation. In the U.S., GE received FDA approval in Sep 2014 for its 3D breast tomosynthesis system and Siemens received FDA approval for its tomosynthesis system in April 2015 which have put additional competitive pressure on Hologic. Moreover, large players such as Fuji and Siemens are developing 3D tomosynthesis systems targeting the U.S. market.

Moreover, primary competitors for the biopsy product line are Devicor Medical Products and part of Danaher Corporation's Leica Biosystems division. In the clinical market, Hologic witnesses competition from several companies including Abbott Laboratories, Siemens, Becton, Dickinson, Qiagen, CareFusion, Sanarus Technologies and Intact Medical Corporation and Roche Diagnostics, among others. Moreover, the FDA has re-classified FFDM devices to class II from class III, thereby making it easier for all medical device companies to bring in similar products in the market.

Subsequently, the approval process for class II devices will require 510(k) clearance, rather than the lengthy PMA application. Though this move by the FDA will enable easier approval in the U.S., we note that it will further intensify competition among medical device companies.

- **Weak Solvency and Capital Structure:** Hologic exited the fiscal fourth quarter with cash and cash equivalents of \$701 million compared with \$744 million at the end of the fiscal third quarter. Meanwhile, total debt came up to \$3.04 billion for the period, compared with \$3.32 billion in the sequentially last reported quarter. This figure is much higher than the quarter-end cash and cash equivalent level. However, if we go by the company's current-year debt level of \$324.9 million, it is lower compared to the cash in hand. This is good news in terms of the company's solvency position as during the year of economic downturn, the company is holding sufficient cash for short-term debt repayment.

The quarter's total debt-to-capital ratio of 0.53 shows a decrease from 0.59 reported at the end of the fiscal third quarter. It reflects a high-leveraged balance sheet. The overall data shows a discouraging solvency level for Hologic.

The times interest earned for the company stands at 9.6%, representing an increase from 3.1% at the end of the fiscal third quarter.

Last Earnings Report

Hologic Q4 Earnings Surpass Estimates, Margins Rise

Hologic reported fourth-quarter fiscal 2020 adjusted earnings per share of \$2.07, up 218.5% year over year. Moreover, the bottom line surpassed the Zacks Consensus Estimate by 69.7%.

The adjustments include charges and benefits related to amortization of acquired intangible assets, MDR expenses and non-income-tax settlement adjustment to name a few.

The company's GAAP earnings per share was \$1.88, up from the loss per share of 46 cents in the year-ago period.

Full-year adjusted earnings per share was \$3.98, reflecting a 63.8% surge from the year-earlier \$2.43. Again, the metric surpassed the Zacks Consensus Estimate by 26.8%.

Full-year GAAP earnings per share was \$4.21, up from the year-earlier loss of 76 cents per share.

Quarter Ending	09/2020
Report Date	Nov 04, 2020
Sales Surprise	7.72%
EPS Surprise	69.67%
Quarterly EPS	2.07
Annual EPS (TTM)	4.00

Revenues in Detail

Revenues grossed \$1.35 billion in the reported quarter, up 55.6% year over year (up 54.2% at CER), including revenues from the divested Medical Aesthetics business in the year-ago period. The metric exceeded the Zacks Consensus Estimate by 7.7%.

Excluding the divested Blood Screening and Medical Aesthetics businesses, total revenues were \$1.34 billion, up 73.3% year over year and 71.7% at CER. This primarily resulted from robust sales of tests related to COVID-19.

Organic revenues (excluding divestitures and the acquired SuperSonic Imagine or SSI business) of \$1.33 billion increased 72.5% year over year and 70.9% at CER.

U.S. revenues of \$994.9 million rose 51.6%, whereas international revenues of \$352.1 million improved 68% year over year or 62.1% at CER.

Organically, revenues in the United States rose 64% year over year to \$985 million in the quarter. International revenues were up 102.2% year over year (up 95% at CER) to \$346.8 million.

Full-year revenues were \$3.78 billion, reflecting a 12.1% increase from the year-ago period. Organic revenue growth for the year was 22%. Revenues surpassed the Zacks Consensus Estimate by 4.4%.

Segments in Detail

Revenues at the **Diagnostics** segment rose 206.1% year over year (up 202.8% at CER) to \$939 million in the quarter under review, with Molecular Diagnostics being the major driver. Molecular Diagnostics' revenues of \$818.9 million climbed 375.8% (up 370.8% at CER), continuing the division's strong performance. However, Blood Screening revenues of \$8.7 million fell 47.9% year over year (down 48.2% at CER).

Revenues at the **Breast Health** segment declined 15.6% from the year-ago period (down 16.2% at CER) to \$289.2 million. This primarily resulted from adverse impacts on demand for this segment's products due to customers' focus on responding to the pandemic, delayed or reduced purchases of capital equipment and rescheduled routine screening appointments. However, consumables and service revenues are gradually recovering and the flat interventional business was aided by the relaunch of the Brevera biopsy system late in the quarter. These developments cushioned the overall segmental decline.

Domestic sales were dismal in this segment in the quarter, with a 16.1% revenue decline year over year and 16.4% drop without SSI. Further, outside the United States, Breast Health sales decreased 13.6% in total and fell 21.1% without SSI.

Revenues at the **GYN Surgical** business fell 12.5% year over year (down 12.9% at CER) to \$100.2 million, while revenues at **Skeletal Health** dropped 25.6% year over year (down 26.3% at CER) to \$18.6 million.

Notably, Hologic no longer reports for the Medical Aesthetics segment post the divestiture of Cynosure Medical Aesthetics business on Dec 30, 2019.

Operational Update

In fiscal fourth quarter, the company-reported adjusted gross margin expanded 1,250 basis points to 74.2%. According to the company, the benefits resulted from sales of SARS-CoV-2 tests and the divestiture of the lower-margin Medical Aesthetics business.

Adjusted operating expenses amounted to \$276.6 million, down 1% year over year. However, the company-reported adjusted operating margin expanded 2,430 basis points to 53.7%.

Financial Update

Hologic exited fiscal 2020 with cash and cash equivalents of \$701 million compared with \$601.8 million at the end of fiscal 2019. Total long-term debt (including current portion) was \$3.04 billion at the end of fiscal 2020 compared with \$3.06 billion at the end of fiscal 2019.

Cumulative net cash provided by operating activities at the end of fiscal 2020 was \$896.6 million compared with \$649.5 million a year ago.

Guidance

Hologic, boosted by the strength in its COVID-19 tests and the ongoing recovery of its other divisions, has provided the financial guidance for first-quarter fiscal 2021.

The company projects revenues within \$1.35-\$1.43 billion (projection of 58.7-67.6% growth rate). The growth rate is projected in the range of 56.6-65.4% at CER and within 71.1-80.8% organically. The Zacks Consensus Estimate for first-quarter fiscal 2021 revenues is pegged at \$1.10 billion.

GAAP earnings per share is estimated within \$1.88-\$2.03, which projects growth of 31.5-42%.

The adjusted earnings per share is estimated within \$2.10-\$2.25, with projected growth of 244.3-268.9%. The Zacks Consensus Estimate for first-quarter fiscal 2020 earnings per share is pegged at \$1.18.

Recent News

Hologic Expands GYN Surgical Arm via Omni Suite Launch: Nov 5, 2020

Hologic launched the Omni Suite, which is a comprehensive surgical offering designed to optimize diagnostic and operative hysteroscopy and includes a Omni 30° hysteroscope and Omni 4K video technology to complement the company's existing portfolio of GYN surgical solutions.

Hologic Receives COVID-19-Related Government Contract: Oct 30, 2020

Hologic announced the receipt of a \$119 million contract from the United States government to expand its production capacity for COVID-19 molecular tests.

Hologic Launches Latest Imaging Technology, to Address Pandemic-Led Screening Backlog: Oct 26, 2020

Hologic announced the commercial availability in Europe of its 3DQuorum Imaging Technology, Powered by Genius AI, which was designed to enhance mammography efficiency and workflow to manage the backlog of women whose routine breast screening was delayed due to the widespread lockdowns.

Hologic's Aptima Assay's EUA Amended by FDA: Oct 6, 2020

Hologic announced that its Aptima SARS-CoV-2 assay, which initially received Emergency Use Authorization (EUA) from the FDA in May, is now authorized for testing of individuals without symptoms or other reasons to suspect COVID-19 infection.

Hologic, BWHI Announce Breast Cancer Screening Commitment: Oct 1, 2020

Hologic, in partnership with the Black Women's Health Imperative (BWHI), announced a multi-year commitment to decreasing breast cancer screening disparities for Black women.

Hologic Receives EUA for its Asymptomatic COVID-19 Testing: Sep 28, 2020

Hologic announced that its Panther Fusion SARS-CoV-2 assay has received EUA from the FDA for testing of individuals without symptoms or other reasons to suspect COVID-19 infection.

Hologic's Aptima Assay Awarded WHO Prequalification: Sep 14, 2020

Hologic announced that its CE-marked Aptima HIV-1 Quant Dx assay has been awarded World Health Organization (WHO) prequalification for testing of dried blood spot samples.

Hologic Updates Breast Biopsy System to Enhance Workflow: Aug 28, 2020

Hologic announced the addition of improved features to its Brevera Breast Biopsy System with CorLumina Imaging Technology.

Hologic's Acesa Health Buyout to Broaden GYN Surgical Line: Aug 25, 2020

Hologic has purchased privately-held Acesa Health Inc. with an aim to broaden its foothold in minimally invasive surgical procedures.

Hologic Validates its Molecular Diagnostic COVID-19 Assays: Aug 11, 2020

Hologic announced that it has validated use of its Aptima and Panther Fusion molecular diagnostic COVID-19 assays with pooled patient samples. The company also completed an emergency use notification to the FDA to make this workflow available to laboratory customers in the United States.

Valuation

Hologic shares are up 43.8% in the year-to-date period and up 64.6% in the trailing 12-month periods. Stocks in the Zacks sub-industry are up 21.6% while the Zacks Medical sector fell 0.2% in the year-to-date period. Over the past year, the Zacks sub-industry is up 24.5% and sector is up 6.6%.

The S&P 500 index is up 9.4% in the year-to-date period and up 14.3% in the past year.

The stock is currently trading at 12.6X Forward 12-months earnings, which compares to 36.3X for the Zacks sub-industry, 22.2X for the Zacks sector and 22.2X for the S&P 500 index.

Over the past five years, the stock has traded as high as 22.4X and as low as 10.8X, with a 5-year median 18.1X. Our Outperform recommendation indicates that the stock will perform above the market. Our \$86 price target reflects 14.4X forward 12-months earnings.

The table below shows summary valuation data for HOLX.

Valuation Multiples - HOLX					
		Stock	Sub-Industry	Sector	S&P 500
P/E F12M	Current	12.55	36.28	22.24	22.24
	5-Year High	22.44	41.88	22.99	23.47
	5-Year Low	10.76	23.17	15.91	15.27
	5-Year Median	18.13	29.22	19.02	17.72

P/S F12M	Current	4.01	4.55	2.80	4.12
	5-Year High	5.07	4.55	3.24	4.30
	5-Year Low	2.36	2.53	2.24	3.17
	5-Year Median	3.67	3.24	2.84	3.67
P/B TTM	Current	7.18	4.70	3.82	6.21
	5-Year High	8.41	4.82	5.09	6.22
	5-Year Low	3.37	2.75	2.96	3.74
	5-Year Median	4.93	3.95	4.30	4.90

As of 11/06/2020

Source: Zacks Investment Research

Industry Analysis Zacks Industry Rank: Bottom 34% (165 out of 249)



Source: Zacks Investment Research

Top Peers

Company (Ticker)	Rec	Rank
STERIS plc (STE)	Outperform	2
Edwards Lifesciences Corporation (EW)	Neutral	3
IDEXX Laboratories, Inc. (IDXX)	Neutral	2
Intuitive Surgical, Inc. (ISRG)	Neutral	3
SONOVA HOLDING (SONVY)	Neutral	2
Teleflex Incorporated (TFX)	Neutral	3
Varian Medical Systems, Inc. (VAR)	Neutral	3
Fresenius Medical Care AGCo. KGaA (FMS)	Underperform	3

The positions listed should not be deemed a recommendation to buy, hold or sell.

Industry Comparison Industry: Medical - Instruments				Industry Peers		
	HOLX	X Industry	S&P 500	SONVY	STE	VAR
Zacks Recommendation (Long Term)	Outperform	-	-	Neutral	Outperform	Neutral
Zacks Rank (Short Term)	1	-	-	2	2	3
VGM Score	B	-	-	D	C	C
Market Cap	19.44 B	160.17 M	23.64 B	16.49 B	15.45 B	15.80 B
# of Analysts	8	2	13	1	4	5
Dividend Yield	0.00%	0.00%	1.56%	0.00%	0.88%	0.00%
Value Score	C	-	-	D	C	C
Cash/Price	0.04	0.13	0.07	0.03	0.02	0.05
EV/EBITDA	61.83	-1.02	13.75	22.92	22.03	28.76
PEG F1	0.78	3.76	2.71	NA	NA	NA
P/B	7.18	3.83	3.33	8.01	4.22	7.58
P/CF	13.60	24.14	13.32	24.07	22.66	30.50
P/E F1	12.10	58.30	21.18	35.85	30.70	33.36
P/S TTM	5.15	4.53	2.63	NA	5.11	4.99
Earnings Yield	8.26%	-2.91%	4.53%	2.79%	3.26%	3.00%
Debt/Equity	1.00	0.06	0.70	0.29	0.28	0.00
Cash Flow (\$/share)	5.52	-0.15	6.92	2.11	8.02	5.70
Growth Score	B	-	-	B	C	C
Historical EPS Growth (3-5 Years)	8.58%	8.32%	10.07%	NA	13.44%	0.16%
Projected EPS Growth (F1/F0)	55.75%	13.98%	0.26%	84.42%	4.92%	33.20%
Current Cash Flow Growth	27.33%	6.03%	5.29%	14.96%	5.66%	7.70%
Historical Cash Flow Growth (3-5 Years)	3.55%	10.08%	8.38%	NA	20.19%	0.79%
Current Ratio	1.79	3.16	1.38	1.11	2.64	1.40
Debt/Capital	50.06%	13.05%	41.97%	22.58%	21.79%	0.00%
Net Margin	29.53%	-20.36%	10.44%	NA	13.97%	8.50%
Return on Equity	45.24%	-19.57%	14.96%	NA	14.44%	18.45%
Sales/Assets	0.56	0.51	0.50	NA	0.56	0.72
Projected Sales Growth (F1/F0)	12.17%	0.00%	0.00%	-4.03%	0.81%	11.29%
Momentum Score	A	-	-	F	A	A
Daily Price Change	-2.11%	0.00%	-0.23%	0.85%	1.40%	0.20%
1-Week Price Change	1.34%	-5.82%	-5.63%	-9.53%	-5.52%	0.14%
4-Week Price Change	9.90%	-2.83%	0.00%	-4.43%	-2.72%	1.10%
12-Week Price Change	10.17%	-4.40%	2.80%	7.60%	14.11%	0.27%
52-Week Price Change	62.45%	-0.84%	2.05%	12.35%	25.13%	40.71%
20-Day Average Volume (Shares)	1,851,296	149,167	1,955,785	18,499	325,612	941,546
EPS F1 Estimate 1-Week Change	0.00%	0.00%	0.00%	0.00%	4.87%	0.00%
EPS F1 Estimate 4-Week Change	2.33%	0.00%	1.27%	35.24%	4.87%	3.42%
EPS F1 Estimate 12-Week Change	1.70%	2.34%	3.13%	15.28%	7.53%	3.42%
EPS Q1 Estimate Monthly Change	45.16%	0.00%	0.51%	NA	9.76%	3.89%

Source: Zacks Investment Research

Zacks Stock Rating System

We offer two rating systems that take into account investors' holding horizons: Zacks Rank and Zacks Recommendation. Each provides valuable insights into the future profitability of the stock and can be used separately or in combination with each other depending on your investment style.

Zacks Recommendation

The Zacks Recommendation aims to predict performance over the next 6 to 12 months. The foundation for the quantitatively determined Zacks Recommendation is trends in the company's estimate revisions and earnings outlook. The Zacks Recommendation is broken down into 3 Levels; Outperform, Neutral and Underperform. Unlike many Wall Street firms, we maintain a balance between the number of Outperform and Neutral recommendations. Our team of 70 analysts are fully versed in the benefits of earnings estimate revisions and how that is harnessed through the Zacks quantitative rating system. But we have given our analysts the ability to override the Zacks Recommendation for the 1200 stocks that they follow. The reason for the analyst over-rides is that there are often factors such as valuation, industry conditions and management effectiveness that a trained investment professional can spot better than a quantitative model.

Zacks Rank

The Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon. The underlying driver for the quantitatively-determined Zacks Rank is the same as the Zacks Recommendation, and reflects trends in earnings estimate revisions.

Zacks Style Scores

The Zacks Style Score is as a complementary indicator to the Zacks rating system, giving investors a way to focus on the highest rated stocks that best fit their own stock picking preferences.

Academic research has proven that stocks with the best Value, Growth and Momentum characteristics outperform the market. The Zacks Style Scores rate stocks on each of these individual styles and assigns a rating of A, B, C, D and F. We also produce the VGM Score (V for Value, G for Growth and M for Momentum), which combines the weighted average of the individual Style Scores into one score. This is perfectly suited for those who want their stocks to have the best scores across the board.

Value Score	C
Growth Score	B
Momentum Score	A
VGM Score	B

As an investor, you want to buy stocks with the highest probability of success. That means buying stocks with a Zacks Recommendation of Outperform, which also has a Style Score of an A or a B.

Disclosures

This report contains independent commentary to be used for informational purposes only. The analysts contributing to this report do not hold any shares of this stock. The analysts contributing to this report do not serve on the board of the company that issued this stock. The EPS and revenue forecasts are the Zacks Consensus estimates, unless indicated otherwise on the reports first page. Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts personal views as to the subject securities and issuers. ZIR certifies that no part of the analysts compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report.

Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Any opinions expressed herein are subject to change.

ZIR is not an investment advisor and the report should not be construed as advice designed to meet the particular investment needs of any investor. Prior to making any investment decision, you are advised to consult with your broker, investment advisor, or other appropriate tax or financial professional to determine the suitability of any investment. This report and others like it are published regularly and not in response to episodic market activity or events affecting the securities industry.

This report is not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned. ZIR or its officers, employees or customers may have a position long or short in the securities mentioned and buy or sell the securities from time to time. ZIR is not a broker-dealer. ZIR may enter into arms-length agreements with broker-dealers to provide this research to their clients. Zacks and its staff are not involved in investment banking activities for the stock issuer covered in this report.

ZIR uses the following rating system for the securities it covers. **Outperform-** ZIR expects that the subject company will outperform the broader U.S. equities markets over the next six to twelve months. **Neutral-** ZIR expects that the company will perform in line with the broader U.S. equities markets over the next six to twelve months. **Underperform-** ZIR expects the company will underperform the broader U.S. equities markets over the next six to twelve months.

No part of this report can be reprinted, republished or transmitted electronically without the prior written authorization of ZIR.

Additional Disclosure

This material represents an assessment of the market and economic environment at a specific point in time and is not intended to be a forecast of future events, or a guarantee of future results. Forward-looking statements are subject to certain risks and uncertainties. Any statements that refer to expectations, projections or characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Actual results, performance, or achievements may differ materially from those expressed or implied.

Returns quoted represent past performance which is no guarantee of future results. Investment returns and principal value will fluctuate so that when shares are redeemed, they may be worth more or less than their original cost. Current performance may be higher or lower than the performance shown.

Investing involves risk; principal loss is possible. There is no guarantee that companies that can issue dividends will declare, continue to pay or increase dividends.

Glossary of Terms and Definitions

52-Week High-Low: The range of the highest and lowest prices at which a stock has traded during the past year. This range is determined based on the stock's daily closing price which may differ from the intra-day high or low. Many investors use it as a technical indicator to determine a stock's current value and future price movement. The idea here is that if price breaks out from the 52-week range, in either direction, the momentum may continue in the same direction.

20-Day Average Volume (Shares): The average number of shares of a company traded in a day over the last 20 days. It is a direct indication of a security's overall liquidity. The higher the average daily trading volume, the easier it is to enter or exit the stock at a desired price with more buyers and sellers being available.

Daily Price Change: This is the percentage difference between a trading day's closing price and the prior trading day's closing price. This item is updated at 9 p.m. EST each day.

1-Week Price Change: This is the percentage change in a stock's closing price over the last 5 trading days. This change reflects the collective buying and selling sentiment over the 1-week period.

A strong weekly price increase for the stock, especially when accompanied by increased volume, is an indication of it gaining momentum.

4-Week Price Change: This is the percentage change in a stock's closing price over the last 20 trading days or past 4 weeks. This is a medium-term price change metric and an indication of the stock gaining momentum.

12-Week Price Change: This is the percentage change of a stock's closing price over the last 60 trading days or past 12 weeks. Similar to 4-week price change, this is a medium-term price change metric. It shows whether a stock has been enjoying strong investor demand, or if it has been in consolidation, or distress over this period.

52-Week Price Change: This is the percentage change in a stock's closing price over the last 260 trading days or past 52 weeks. This long-term price change metric is a good reference point for investors. Some investors seek stocks with the best percentage price change over the last 52 weeks, expecting the momentum to continue.

Market Cap: The number of outstanding common shares of a company times its latest price per share. This figure represents a company's size, which indicates various characteristics, including price stability and risk, in which investors could be interested.

Year-To-Date Price Change: Change in a stock's daily closing price in the period of time beginning the first day of the current calendar year through to the previous trading day.

of Analysts: Number of EPS estimates used in calculating the current-quarter consensus. These estimates come from the brokerage analysts tracking this stock. However, the number of such analysts tracking this stock may not match the number of estimates, as all brokerage analysts may not come up with an estimate or provide it to us.

Beta: A measure of risk commonly used to compare the volatility of a stock to the overall market. The S&P 500 Index is the base for calculating beta and carries a value of 1. A stock with beta below 1 is less risky than the market as a whole. And a stock with beta above 1 is riskier.

Dividend: The portion of earnings a company is expected to distribute to its common shareholders in the next 12 months for each share they own. Dividends are usually paid quarterly. Dividend payments reflect positively on a company and help maintain investors' trust. Investors typically find dividend-paying stocks appealing because the dividend adds to any market price appreciation to result in higher return on investment (ROI). Moreover, a steady or increasing dividend payment provides investors a cushion in a down market.

Dividend Yield: The ratio of a company's annual dividend to its share price. The annual dividend used in the ratio is calculated based on the most recent dividend paid by the company. Dividend yield is an estimate of the dividend-only return from a stock in the next 12 months. Since dividend itself doesn't change frequently, dividend yield usually changes with a stock's price movement. As a result, often an unusually high dividend yield is a result of weak stock price.

S&P 500 Index: The Standard & Poor's 500 (S&P 500) Index is an unmanaged group of securities considered to be representative of the stock market in general. It is a market-capitalization-weighted index of stocks of the 500 largest U.S. companies. Each stock's weight in the index is proportionate to its market value.

Industry: One of the 250+ groups that Zacks classifies all stocks into based on the nature of business. These groups are termed as expanded (aka "X") industries and map to their respective (economic) sectors; Zacks has 16 sectors.

Zacks Industry Rank: The Zacks Industry Rank is determined by calculating the average Zacks Rank for all stocks in the industry and then assigning an ordinal rank to it. For example, an industry with an average Zacks Rank of 1.6 is better than an industry with an average Zacks Rank of 2.3. So, the industry with the better average Zacks Rank would get a better Zacks Industry Rank. If an industry has the best average Zacks Rank, it would be considered the top industry (1 out of 250+), which would place it at the top 1% of Zacks-ranked industries. Studies have shown that roughly half of a stock's price movement can be attributed to the industry group it belongs to. In fact, the top 50% of Zacks-ranked industries outperforms the bottom 50% by a factor of more than 2 to 1.

Last EPS Surprise: The percentage deviation of a company's last reported earnings per share from the Zacks Consensus Estimate. Companies with a positive earnings surprise are more likely to surprise again in the future (or miss again if they recently missed).

Last Sales Surprise: The percentage deviation of a company's last reported sales from the Zacks Consensus Estimate.

Expected Report Date: This is an estimated date of a company's next earnings release. The information originated or gathered by Zacks Investment Research from its information providers or publicly available sources is the basis of this estimate.

Earnings ESP: The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the yet-to-be reported quarter. The Most Accurate Estimate is the most recent version of the Zacks Consensus EPS Estimate. The idea here is that analysts revising their estimates closer to an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only. A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time.

Periods:

TTM: Trailing 12 months. Using TTM figures is an effective way of analyzing the most-recent financial data in an annualized format that helps neutralize the effects of seasonality and other quarter-to-quarter variation.

F1: Current fiscal year. This period is used to analyze the estimates for the ongoing full fiscal year.

F2: Next fiscal year. This period is used to analyze the estimates for the next full fiscal year.

F12M: Forward 12 months. Using F12M figures is an effective way of analyzing the near-term (the following four unreported quarters) estimates in an annualized manner. Instead of typically representing estimates for the full fiscal year, which may not represent the nitty-gritty of each quarter, F12M figures suggest an all-inclusive annualized estimate for the following four quarters. The annualization helps neutralize the potential effects of seasonality and other quarter-to-quarter variations.

P/E Ratio: The price-to-earnings ratio measures a company's current market price per share relative to its earnings per share (EPS). Usually, the trailing-12-month (TTM) EPS, current-fiscal-year (F1) EPS estimate, or forward-12-month (F12M) EPS estimate is used as the denominator. In essence, this ratio shows what the market is willing to pay today for each dollar of EPS. In other words, this ratio gives a sense of what the relative value of the company is at the already reported level of earnings or at a future level of earnings.

It is one of the most widely-used multiples for determining the value of a company and helps comparing its valuation with that of a competitor, the industry group or a benchmark.

PEG Ratio: The price/earnings to growth ratio is a stock's P/E ratio using current fiscal year (F1) EPS estimate divided by its expected EPS growth rate over the coming 3 to 5 years. This ratio essentially determines a stock's value by factoring in the company's expected earnings growth and is thus believed to provide a more complete picture than just the P/E ratio, particularly for faster-growing companies.

P/S Ratio: The price-to-sales ratio is calculated as a company's current price per share divided by trailing 12 months (TTM) sales or revenues per share. This ratio shows what the market is willing to pay today for each dollar of TTM sales per share. The P/S ratio is at times the only valuation metric when the company has yet to become profitable.

Cash/Price Ratio: The cash-to-price ratio or Cash Yield is calculated as cash and marketable securities per share divided by the company's current share price. Like the earnings yield, which shows the anticipated yield (or return) on a stock from earnings for each dollar invested, the cash yield does the same, with cash being the source of return instead of earnings. For example, a cash/price ratio of 0.08 suggests a return of 8% or 8 cents for every \$1 investment.

EV/EBITDA Ratio: The EV/EBITDA ratio, also known as Enterprise Multiple, is calculated as a company's enterprise value (market capitalization + value of total long-term debt + book value of preferred shares - cash and marketable securities) divided by EBITDA (earnings before interest, taxes, depreciation and amortization). Usually, trailing-12-month (TTM) or forward-12-month (F12M) EBITDA is used as the denominator.

EV/Sales Ratio: The enterprise value-to-sales ratio is calculated as a company's enterprise value (market capitalization + value of total long-term debt + book value of preferred shares - cash and marketable securities) divided by annual sales. It is an expansion of the P/S valuation, which uses market value instead of enterprise value. The EV/Sales ratio is perceived as more accurate than P/S, in part, because the market capitalization does not take a company's debt into account when valuing it.

EV/CF Ratio: The enterprise value-to-cash flow ratio is calculated as a company's enterprise value (market capitalization + value of total long-term debt + book value of preferred shares - cash and marketable securities) divided by the trailing-12-month (TTM) operating cash flow. It's a measure of how long it would take to buy the entire business if you were able to use all the company's operating cash flow.

The EV/CF ratio is perceived as more accurate than the P/CF ratio, in part, because the market price does not take a company's debt into account when valuing it.

EV/FCF Ratio: The enterprise value-to-free cash flow metric compares a company's enterprise value to its trailing-12-month (TTM) free cash flow (FCF). This metric is very similar to the EV/CF ratio, but is considered a more exact measure owing to the fact that it uses free cash flow, which subtracts capital expenditures (CAPEX) from a company's total operating cash flow, thereby reflecting the actual cash flow available for funding growth activities and payments to shareholders.

P/EBITDA Ratio: The P/EBITDA ratio is calculated as a company's per share market value divided by EBITDA (earnings before interest, taxes, depreciation, and amortization). This metric is very similar to the EV/EBITDA ratio, but is considered a little less exact measure as it uses market price, which does not take a company's debt into account. However, since EBITDA is often considered a proxy for cash income, the metric is used as a measure of what the market is willing to pay today for each dollar of the company's cash profitability in the trailing 12 months (TTM) or forward 12 months (F12M).

P/B Ratio: The price-to-book ratio is calculated as a company's current price per share divided by its book value (total assets – liabilities – preferred stocks) per share. In short, the book value is how much a company is worth. In other words, it reflects the total value of a company's assets that its common shareholders would receive if it were to be liquidated. So, the P/B ratio indicates whether you're paying higher or lower than what would remain if the company went bankrupt immediately. Investors typically use this metric to determine how a company's stock price stacks up to its intrinsic value.

P/TB Ratio: The price-to-tangible-book value ratio is calculated as a the per share market value of a company divided by the value of its tangible assets (total assets – liabilities – preferred stocks – intangible assets) per share. Tangible book value is the same thing as book value except it excludes the value of intangible assets to get a step closer to the baseline value of the company.

P/CF Ratio: The price-to-cash flow ratio measures a company's per share market price relative to its trailing-12-month (TTM) operating cash flow per share. This metric is used to determine whether a company is undervalued or overvalued relative to another stock, industry or sector. And like the P/E ratio, a lower number is typically considered better from the value perspective.

One of the reasons why P/CF ratio is often preferred over P/E ratio is the fact that operating cash flow adds back non-cash expenses such as depreciation and amortization to net income. This feature helps valuing stocks that have positive cash flow but are not profitable because of large noncash charges.

P/FCF Ratio: The price-to-free cash flow ratio is an extension of P/CF ratio, which uses trailing-12-month (TTM) free cash flow per share instead of operating cash flow per share. This metric is considered a more exact measure than P/CF ratio, as free cash flow subtracts capital expenditures (CAPEX) from a company's total operating cash flow, thereby reflecting the actual cash flow available for funding activities that generate additional revenues.

Earnings Yield: The earnings yield is calculated as current fiscal year (F1) EPS estimate divided by the company's current share price. The ratio, which is the inverse of the P/E ratio, measures the anticipated yield (or return) from earnings for each dollar invested in a stock today.

For example, earnings yield for a stock, which is trading at \$35 and expected to earn \$3 per share in the current fiscal year (F1), would be 0.0857 ($3/35 = 0.0857$) or 8.57%. In other words, for \$1 invested in the stock today, the yield from earnings is anticipated to be 8.57 cents.

Investors most commonly compare the earnings yield of a stock to that of a broad market index (such as the S&P 500) and prevailing interest rates, such as the current 10-year Treasury yield. Since bonds and stocks compete for investors' dollars, stock investors typically demand a higher yield for the extra risk they assume compared to investors of U.S. Treasury-backed securities that offer virtually risk-free returns. This additional return is referred to as the risk premium.

Debt/Equity Ratio: The debt-to-equity ratio is calculated as a company's total liabilities divided by its shareholder equity. This metric is used to gauge a company's financial leverage. In other words, it is a measure of the degree to which a company is financing its operations through debt versus its own funds. The higher the ratio, the higher the risk for shareholders.

However, this ratio is difficult to compare across industry groups where ideal amounts of debt vary. Some businesses are more capital intensive than others and typically require higher debt to finance their operations. So, a company's debt-to-equity ratio should be compared with other companies in the same industry.

Cash Flow (\$/share): Cash flow per share is calculated as operating cash flow (after-tax earnings + depreciation + other non-cash charges) divided by common shares outstanding. It is used by many investors as a measure of a company's financial strength. Since cash flow per share takes into consideration a company's ability to generate cash by adding back non-cash expenses, it is regarded by some as a more accurate measure of a company's financial situation than earnings per share, which could be artificially deflated.

Current Ratio: The current ratio or liquidity ratio is a company's current assets divided by its current liabilities. It measures a company's ability to pay short-term obligations. A current ratio that is in line with the industry average or slightly higher is generally considered acceptable. A current ratio that is lower than the industry average would indicate a higher risk of distress or default. A higher number is usually better. However, a very high current ratio compared to the industry average could be an indication of inefficient use of assets by management.

Debt/Capital Ratio: Debt-to-capital ratio is a company's total debt (interest-bearing debt + both short- and long-term liabilities) divided its total capital (interest-bearing debt + shareholders' equity). It is a measure of a company's financial leverage. All else being equal, the higher the debt-to-capital ratio, the riskier the stock.

However, this ratio can vary widely from industry to industry, the ideal amount of required debt being different. Some businesses are more capital intensive than others and typically require higher debt to finance their operations. So, a company's debt-to-capital ratio should be compared with the same for its industry.

Net Margin: Net margin is calculated as net income divided by sales. It shows how much of each dollar in sales generated by a company translates into profit. For example, if a company's net margin is 15%, its net income is 15 cents for every \$1 of sales it makes.

A change in margin can reflect either a change in business conditions, or a company's cost controls, or both. If a company's expenses are growing faster than sales, its net margin will decline. However, different net margin rates are considered good for different industries, so it's better to compare net margin rates of companies in the same industry group.

Return on Equity: Return on equity (ROE) is calculated as trailing-12-month net income divided by trailing-12-month average shareholder equity (including reinvested earnings). This metric is considered a measure of how effectively management is using a company's assets to generate profits. For example, if a company's ROE is 10%, it creates 10 cents profits for every \$1 shareholder equity, which is basically the company's assets minus debt. A company's ROE deemed good or bad depends on what's normal for its peers or industry group.

Sales/Assets Ratio: The sales-to-assets ratio or asset utilization ratio or asset turnover ratio is calculated as a company's annual sales divided by average assets (average of assets at the beginning of the year and at the year's end). This metric helps investors understand how effectively a company is using its assets to generate sales. For example, a sales-to-assets ratio of 2.5 indicates that the company generated \$2.50 in sales for every \$1 of assets on its books.

The higher the sales-to-assets ratio, the better the company is performing. However, similar to many other ratios, the asset turnover ratio tends to be higher for companies in certain industries/sectors than in others. So, a company's sales-to-assets ratio should be compared with the same for its industry/sector.

Historical EPS Growth (3-5 Years): This is the average annual (trailing-12-month) EPS growth rate over the last 3-5 years. This metric helps investors see how a company's EPS has grown from a long-term perspective.

Note: There are many factors that can influence short-term numbers — a recession will reduce this number, while a recovery will inflate it. The longterm perspective helps smooth out short-term events.

Projected EPS Growth (F1/F0): This is the estimated EPS growth rate for the current financial year. It is calculated as the consensus estimate for the current fiscal year (F1) divided by the reported EPS for the last completed fiscal year (F0).

Current Cash Flow Growth: It measures the latest year-over-year change in operating cash flow. Cash flow growth tells an investor how quickly a company is generating inflows of cash from operations. A positive change in the cash flow is desired and shows that more 'cash' is coming in than going out.

Historical Cash Flow Growth (3-5 Years): This is the annualized change in cash flow over the last 3-5 years. The change in a longer period helps put the current reading into proper perspective. By looking at the rate, rather than the actual dollar value, the comparison across the industry and peers becomes easier.

Projected Sales Growth (F1/F0): This metric looks at the estimated sales growth for the current year. It is calculated as sales estimate for the current fiscal year (F1) divided by the reported sales for the last completed fiscal year (F0).

Like EPS growth, a higher rate is better for sales growth. A look at a company's projected sales growth instantly tells you what the outlook is for their products and services. However, different sales growth rates are considered good for different industries, so it's better to compare sales growth rates of companies in the same industry group.

EPS F1 Estimate 1-Week Change: The percentage change in the Zacks Consensus EPS estimate for the current fiscal year over the past week. The change in a company's consensus EPS estimate (or earnings estimate revision) has proven to be strongly correlated with the near-term price movement of its shares. It is an integral part of the Zacks Rank.

If a stock's consensus EPS estimate is \$1.10 now versus \$1.00 a week ago, that will be reflected as a 10% upward revision. If, on the other hand, it went from \$1.00 to 90 cents, that would be a 10% downward revision.

EPS F1 Estimate 4-Week Change: The percentage change in the Zacks Consensus EPS estimate for the current fiscal year over the past four weeks.

A stock's earnings estimate revision in a 1-week period is important. But it's more meaningful to look at the longer-term revision. And, of course, the 4-week change helps put the 1-week change into proper perspective.

EPS F1 Estimate 12-Week Change: The percentage change in the Zacks Consensus EPS estimate for the current fiscal year over the past 12 weeks.

This metric essentially shows how the consensus EPS estimate has changed over a period longer than 1 week or 4 weeks.

EPS Q1 Estimate Monthly Change: The percentage change in the Zacks Consensus EPS estimate for the current fiscal quarter over the past four weeks.

While the revision in consensus EPS estimate for the current fiscal year is strongly correlated with the near-term price movement of its shares, the estimate revision for the current fiscal quarter is an important metric as well, especially over the short term, and particularly as a stock approaches its earnings date. If a stock's Q1 EPS estimate decreases ahead of its earnings release, it's usually a negative sign, whereas an increase is a positive sign.